Artelo Biosciences, Inc.SEC Filings
|
|
All SEC filings by Artelo Biosciences, Inc. (ARTL) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q/A | Quarterly report | View Diff | Aug 20, 2026 | |
| 10-Q | Quarterly report | View Diff | Aug 12, 2026 | |
| ARS | Annual report to shareholders | Jun 5, 2026 | ||
| 10-Q | Quarterly report | View Diff | May 14, 2026 | |
| 10-K | Annual report | View Diff | Feb 24, 2026 | |
| ARS | Annual report to shareholders | Dec 11, 2025 | ||
| 10-Q | Quarterly report | View Diff | Nov 12, 2025 | |
| 10-Q | Quarterly report | View Diff | Aug 13, 2025 | |
| 10-Q | Quarterly report | View Diff | May 13, 2025 | |
| 10-K | Annual report | View Diff | Mar 3, 2025 |
Events
| 8-K | Artelo Biosciences Announces Reverse Stock Split | Aug 27, 2026 | ||
| 8-K | Current report | Jul 17, 2026 | ||
| 8-K | Entry Into a Material Definitive Agreement | May 27, 2026 | ||
| 8-K | Termination of a Material Definitive Agreement | May 15, 2026 | ||
| 8-K | Other Events | Apr 7, 2026 | ||
| 8-K | Artelo Biosciences Announces $11.0 Million Private Placement | Mar 30, 2026 | ||
| 8-K | Artelo Biosciences Expands Art27.13 Development | Mar 26, 2026 | ||
| 8-K | Entry Into a Material Definitive Agreement | Mar 18, 2026 | ||
| 8-K | Index to Audited Financial Statements | Mar 17, 2026 | ||
| 8-K | Artelo Biosciences Announces Reverse Stock Split | Mar 6, 2026 |
Registrations and Prospectuses
| 424B5 | Prospectus supplement for primary offering | May 26, 2026 | ||
| 424B5 | Prospectus supplement for primary offering | May 18, 2026 | ||
| S-3/A | Shelf registration | View Diff | May 14, 2026 | |
| S-3 | Shelf registration | View Diff | May 4, 2026 | |
| 424B3 | Prospectus supplement | Apr 16, 2026 | ||
| S-1 | IPO registration | View Diff | Apr 7, 2026 | |
| D | $11.00 Mm in Equity / Options / Securities to Be Acquired, Sold $11.00 Mm, 2 Investors | Apr 6, 2026 | ||
| D | $315.00 K in Debt, Sold $315.00 K, 1 Investor | Mar 27, 2026 | ||
| D | $113.00 K in Debt, Sold $113.00 K, 1 Investor | Mar 27, 2026 | ||
| D | $237.30 K in Debt, Sold $237.30 K, 1 Investor | Mar 27, 2026 |
Proxies
| DEFA14A | Additional proxy soliciting materials | Jul 16, 2026 | ||
| DEFA14A | Additional proxy soliciting materials | Jul 15, 2026 | ||
| DEFA14A | Additional proxy soliciting materials | Jul 2, 2026 | ||
| PRER14A | Preliminary revised proxy | Jun 22, 2026 | ||
| DEFA14A | Additional proxy soliciting materials | Jun 5, 2026 | ||
| DEF 14A | Definitive proxy | View Diff | Jun 5, 2026 | |
| PRE 14A | Preliminary proxy | View Diff | May 26, 2026 | |
| DEFA14A | Additional proxy soliciting materials | Jan 7, 2026 | ||
| DEF 14A | Definitive proxy | View Diff | Dec 11, 2025 | |
| DEF 14A | Definitive proxy | View Diff | Aug 7, 2025 |
Other
| EFFECT | Notice of effectiveness | May 20, 2026 | ||
| EFFECT | Notice of effectiveness | Apr 16, 2026 | ||
| CORRESP | Correspondence with SEC | Apr 13, 2026 | ||
| UPLOAD | Letter from SEC | Apr 13, 2026 | ||
| EFFECT | Notice of effectiveness | Mar 31, 2026 | ||
| EFFECT | Notice of effectiveness | Mar 26, 2026 | ||
| CORRESP | Correspondence with SEC | Mar 25, 2026 | ||
| CORRESP | Correspondence with SEC | Mar 20, 2026 | ||
| CORRESP | Correspondence with SEC | Mar 20, 2026 | ||
| UPLOAD | Letter from SEC | Mar 13, 2026 |
Ownership
| SC 13G/A | Beneficial ownership report | Aug 14, 2026 | ||
| SC 13G/A | Beneficial ownership report | Aug 13, 2026 | ||
| 4 | Matsui Connie | Jul 21, 2026 | ||
| 4 | Blayney Douglas | Jul 21, 2026 | ||
| 4 | Reyes Gregory | Jul 21, 2026 | ||
| 4 | Emanuele Robert Martin | Jul 21, 2026 | ||
| 4 | Kelly Steven | Jul 21, 2026 | ||
| 4 | Favorito Tamara A | Jul 21, 2026 | ||
| SC 13G | Beneficial ownership report | May 15, 2026 | ||
| SC 13G | Beneficial ownership report | Apr 3, 2026 |